Sarcopenic Obesity in Liver Cirrhosis

Version	Summary	Created by	Modification	Content Size	Created at	Operation
1		Hiroki Nishikawa	+ 3045 word(s)	3045	2021-04-14 08:46:56	\|
2	format correct	Conner Chen	Meta information modification	3045	2021-04-20 10:06:06	\|

This entry is adapted from the peer-reviewed paper 10.3390/ijms22041917

The picture of chronic liver diseases (CLDs) has changed considerably in recent years. One of them is the increase of non-alcoholic fatty liver disease. More and more CLD patients, even those with liver cirrhosis (LC), tend to be presenting with obesity these days. The annual rate of muscle loss increases with worsening liver reserve, and thus LC patients are more likely to complicate with sarcopenia. LC is also characterized by protein-energy malnutrition (PEM). Since the PEM in LC can be invariable, the patients probably present with sarcopenic obesity (Sa-O), which involves both sarcopenia and obesity. Currently, there is no mention of Sa-O in the guidelines; however, the rapidly increasing prevalence and poorer clinical consequences of Sa-O are recognized as an important public health problem, and the diagnostic value of Sa-O is expected to increase in the future. Sa-O involves a complex interplay of physiological mechanisms, including increased inflammatory cytokines, oxidative stress, insulin resistance, hormonal disorders, and decline of physical activity. The pathogenesis of Sa-O in LC is diverse, with a lot of perturbations in the muscle–liver–adipose tissue axis.

liver cirrhosis sarcopenic obesity mechanism

1. Sarcopenia and Sarcopenic Obesity in Liver Cirrhosis

Sarcopenia refers to the loss of skeletal muscle mass (SMM) and muscle strength or physical function ^[1]. Sarcopenia is rapidly evolving in the clinical research fields, especially in the last few years, after the proposal of its concept by Irwin Rosenberg in 1989 ^[2]. Primary sarcopenia is defined as a condition in which SMM and muscle strength or physical function decline with aging, while secondary sarcopenia is defined as a condition in which SMM and muscle strength or physical function are impaired due to underlying diseases ^[3]^[4]. In recent years, a large amount of evidence on sarcopenia has been accumulated, and the disease has been registered in ICD-10, and sarcopenia is now recognized as a disease rather than a concept.

Liver cirrhosis (LC) is the end-stage form of chronic liver disease (CLD) and presents with a variety of complications. Liver cirrhosis (LC) is a representative disease that causes secondary sarcopenia ^[5]. LC leads to secondary sarcopenia, due to characteristic conditions such as protein-energy malnutrition (PEM). In cirrhotic patients, fasting for only 6–10 h is equivalent to fasting for 2–3 days in healthy individuals, which is also associated with the development of sarcopenia ^[6]. In LC patients, there is an amino acid imbalance with the decrease of branched-chain amino acids (BCAAs) and increase of aromatic amino acids ^[5]. BCAAs are amino acids that are metabolized by muscles, to detoxify ammonia, and are a good source of energy for the liver ^[5]. BCAAs were found to improve homeostasis model assessment of insulin resistance (HOMA-IR) scores and the function of beta cells in CLD patients ^[7]. The complication rate of sarcopenia in LC patients is reported to be 30–70%, which is obviously high, considering that the complication rate of sarcopenia in inflammatory bowel disease (a typical disease that causes secondary sarcopenia) is about 20% ^[8]. This fact may be related to both the fact that cirrhosis is likely to be complicated with secondary sarcopenia and the fact that Japanese LC patients are aging. Direct-acting antivirals can almost eliminate the virus in patients with cirrhosis C, and nucleoside analogues can also control the disease in patients with cirrhosis B. As a result, the survival has significantly improved, but at the same time, Japanese LC patients have become older. In cirrhotic patients, the annual rate of SMM loss was reported to be 1.3% in Child-Pugh A, 3.5% in Child-Pugh B, and 6.1% in Child-Pugh C ^[9]. The annual rate of muscle loss increases with worsening liver reserve, which is clearly higher than the 1% annual rate of muscle loss in the general elderly population ^[9].

Sarcopenic obesity (Sa-O) was first defined by Baumgartner as the co-existence of sarcopenia and obesity, as measured by dual-energy X-ray absorptiometry, describing an interplay between obesity and sarcopenia related to physical activity decline and reduced energy expenditure ^[10]. The rapidly increasing prevalence and poor clinical consequences of Sa-O are recognized as an important public health problem in the aging population. The main alterations in body composition due to aging include an increase in body fat and a decrease in SMM, which are not accompanied by much change in BMI ^[11]. These alterations of body composition are often difficult to notice on the outside, and detection tends to be delayed, making it easier for lifestyle-related diseases and other conditions to progress without being noticed. The picture of CLDs has changed considerably in recent years. One of them is the increase of non-alcoholic fatty liver disease (NAFLD). In Asia, NAFLD prevalence increased significantly over time (25.3% between 1999 and 2005, 28.5% between 2006 and 2011, and 33.9% between 2012 and 2017; p < 0.0001) ^[12]. More and more CLD patients, even those with LC, tend to be presenting with obesity these days, due to the changes of lifestyle. As PEM in LC can be invariable, the patients probably present with Sa-O. In most cases, sarcopenia and obesity are judged separately, and Sa-O is considered when both are present. However, the biggest problem in clinical studies of Sa-O is the lack of a common definition, despite the fact that Asian Working Group for Sarcopenia (AWGS) and European Working Group on Sarcopenia in Older People (EWGSOP) recommend a definition of sarcopenia ^[3]^[4]. The indexes of obesity and the definition of obesity are not consistent among studies, and thus the frequency of Sa-O varies widely.

2. Obesity Paradox and Liver Cirrhosis

Obesity can be a major risk factor for morbidity and mortality in metabolic and cardiovascular diseases and is an important health threat. WHO proposes the definition of obesity according to body mass index (BMI): ≥30 kg/m² in Caucasians, and ≥25 kg/m² in Asians, with further classifications into class I, II, and III obesity ^[13]^[14]. The prevalence of obesity in adults has doubled since 1980 and globally continues to elevate ^[11]. Obesity can accelerate the progression of LC status, but the data are not consistent on the extent to which it affects mortality. This discrepancy is partly due to the lack of correction for body weight for excess body water and partly due to the obesity paradox ^[15]^[16]^[17]. Obesity paradox is a phenomenon in which obese people are found to have a reduced risk of death compared to people with standard weight, and it has attracted attention in considering the pathological significance of obesity. Karagozian et al. reported, in their large cohort study (32,605 LC subjects), that crude mortality was lower for obese LC subjects than for non-obese LC subjects (2.7% vs. 3.5%, p = 0.02), and in their multivariate analysis, obesity significantly lowered a risk of inpatient mortality (hazard ratio (HR) = 0.73, p = 0.02) ^[16]. Most studies on obesity paradox use BMI as an index of obesity, but obesity is essentially a condition associated with increased adipose tissue mass, and it is difficult to accurately assess adipose tissue mass with BMI, which includes muscle mass and bone mass in addition to fat. There are cases of excess visceral fat even when BMI is within the normal range, and attention should also be paid to the amount of visceral fat in cases with sarcopenia.

3. Prevalence and Definition of Sarcopenic Obesity

Sarcopenia and obesity are closely related. Sa-O involves a complex interplay of physiological mechanisms, including increased inflammatory cytokines, oxidative stress, insulin resistance, hormonal disorders, and decline of physical activity ^[10]^[11]^[18]^[19]. However, as mentioned above, there is no mention of Sa-O in either the AWGS guidelines or the EWGSOP guidelines. Existing LC-related reports are limited, but they have shown that a Sa-O prevalence in cirrhotic patients is 2% to 42% ^[20]^[21]^[22]^[23]^[24]^[25]^[26]^[27]^[28]^[29]. The definition and prevalence of Sa-O in LC patients are summarized in Table 1. The most commonly used definition of Sa-O is the combined assessment of skeletal muscle index (SMI, SMM measured by computed tomography (CT, L3 level) corrected for height squared) and BMI (>25 or 30 kg/m²), and in most LC-related studies regarding Sa-O, grip strength and walking speed are not incorporated in the definition. However, there are no internationally standardized diagnostic criteria for Sa-O. This may be, in part, due to differences in BMI and SMM among races.

Table 1. Definition and prevalence of sarcopenic obesity (Sa-O) among studies.

Author (Country and Year)	Diagnostic Method (Skeletal Muscle)	Diagnostic Method (Fat Mass)	Definition (Sarcopenia)	Definition (Obesity)	Cutoff Point for Sarcopenia	Cutoff Point for Obesity	Prevalence of Sa-O (%)
Vidot H., et al. (Australia, 2019) ^[29]	CT (PMI, L3)‘	BMI	PMM/height² (mm²/m²)	kg/m²	M: <545 F: <385	M: ≥30 F: ≥30	28%
Kroh, et al. (Germany, 2019) ^[27]	CT (L3 level)	Body fat percentage	SMM/height² (cm²/m²)	%	M: <43 (BMI < 25) or <53 (BMI >25), F: <41	Top two quintiles	23%
Kobayashi, et al. (Japan, 2019) ^[22]	CT (L3 level)	CT (Umbilicus level)	SMM/height² (cm²/m²)	cm²	M: <40.31 F: <30.88	M: ≥100 F: ≥100	7%
Kamo, et al. (Japan, 2019) ^[26]	CT (L3 level)	VFA or BMI	SMM/height² (cm²/m²)	cm² or kg/m²	M: <40.31 F: <30.88	VFA ≥ 100 or BMI ≥ 25	VFA: 3% BMI: 2%
Bering, et al. (Brazil, 2018) ^[28]	DXA and GS	Body fat percentage	SMM/height² (cm²/m²) and kg	%	M: <7.46 and 30 (GS) F: <5.45 and 20 (GS)	M: ≥27 F: ≥37	14%
Hammad, et al. (Japan, 2017) ^[25]	CT (PMI, L3)	BMI	PMM/height² (cm²/m²)	kg/m²	M: <6.36 F: <3.92	M: ≥25 F: ≥25	5%
Carias, et al. (USA, 2016) ^[23]	CT (L3-L4 level)	BMI	SMM/height² (cm²/m²)	kg/m²	M: <52.4 F: <38.5	M: ≥30 F: ≥30	42%
Hara, et al. (Japan, 2016) ^[24]	BIA (ULM)	CT (Umbilicus level)	ULM/height² (cm²/m²)	cm²	M: <1.7 F: <1.2	M: ≥100 F: ≥100	9%
Montano-Loza, et al. (Canada, 2016) ^[20]	CT (L3 level)	BMI MA at the L3 level	SMM/height² (cm²/m²)	kg/m² MA	M: <43 (BMI < 25) or <53 (BMI > 25), F: <41	M and F: BMI ≥ 25 or MA < 33 HU	20%
Kaibori, et al. (Japan, 2015) ^[21]	CT (L3 level)	CT (multifidus muscle at the umbilicus level)	SMM/height² (cm²/m²)	IMAC	M: <44 F: <38	M: −0.44 F: −0.31	NA

CT; computed tomography, BMI; body mass index, PMI; psoas muscle index, PMM; psoas muscle mass, M; male, F; female, SMM; skeletal muscle mass, VFA; visceral fat area, DXA; dual-energy X-ray absorptiometry, GS; grip strength, BIA; bioelectrical impedance analysis, ULM; upper limb mass, MA; muscle attenuation. IMAC; intramuscular adipose content, HU; Hounsfield Unit, NA; not assessed.

4. Molecular Mechanism and Liver Diseases

Various molecular biological findings and clinical analyses have been reported on the mechanisms of metabolic abnormalities associated with LC. The BMI of LC patients in Japan is almost the same as that of general population of the same age, and one in four LC patients is obese with a BMI ≥ 25 kg/m², and only a few LC patients have a BMI < 18.5 kg/m² ^[30]. In our 226 Japanese LC patients, 70 patients (31%) had a BMI ≥ 25 kg/m², and 14 patients (6%) a BMI < 18.5 kg/m².

Clinical features of glucose metabolism in LC patients are as follows: (1) not-so-higher fasting blood glucose in the early morning, (2) higher blood insulin concentration, (3) higher HOMA-IR level in more than half of LC patients, and (4) postprandial hyperglycemia. In addition, hepatitis C virus infection, which is the most common cause of cirrhosis in Japan, can be a cause of increased hepatic steatosis and insulin resistance through the action of hepatitis C virus core protein ^[31]^[32]. There are many reports that insulin resistance and obesity are important risk factors for carcinogenesis in cirrhotic patients ^[33]. The pathogenesis of Sa-O in LC is diverse, with a lot of perturbations in the muscle-liver–adipose tissue axis.

Insulin has metabolic effects that promote anabolism and inhibit catabolism of nutrients. As skeletal muscle is the target organ of insulin, loss of SMM is a cause of insulin resistance ^[34]. Insulin resistance in skeletal muscle is involved in the pathogenesis of sarcopenia and may contribute to obesity ^[34]. Sarcopenia can increase the risk of liver fibrosis progression in patients with obesity, insulin resistance, metabolic syndrome, and liver steatosis, which can easily fall into Sa-O ^[35]^[36]^[37]. LC patients are likely to be involved in insulin resistance and chronic inflammation ^[38]. Oxidative stress is thought to be a mechanism linking insulin resistance and inflammation to sarcopenia. Oxidative stress can damage mitochondria and nuclear DNA, stimulate apoptosis, and lead to muscle fiber atrophy and myocyte loss ^[39]. Dysbiosis indicates a state where the diversity of gut microbiota and the number of bacteria in the gut are reduced ^[5]. LC associated dysbiosis also induces oxidative stress ^[5]. Testosterone, which is important for skeletal muscle formation, is decreased in LC patients ^[40]. A previous randomized trial emphasized the significance of testosterone supplementation therapy on the improvement of SMM in male LC patients ^[40].

Adipose tissue produces inflammatory proteins and cytokines, such as CRP, TNF-α, IL-6, and IL1β, forming a chronic inflammatory environment that leads to muscle atrophy and sarcopenia ^[41]. Adipose tissue produces a number of hormones and bioactive substances, including leptin and adiponectin. Adiponectin is present in large amounts in the blood, declines with fat accumulation, and increases with weight loss. Adiponectin has the ability to improve insulin sensitivity throughout the body. Adiponectin stimulates the AMPK pathway and suppresses the NF-κB pathway. It also suppresses the production of TNF-α and IFN-γ secreted by monocytes, macrophages, and dendritic cells, and it increases anti-inflammatory cytokines. TNF-α and IFN-s-dependent muscle decline is linked to NF-κB pathway ^[42]. The AMPK stimulation of adiponectin is attenuated in obesity ^[41]. The obesity-induced suppression of adiponectin leads to persistent chronic inflammation in muscle tissue ^[41]. Especially in patients with NAFLD, the protective effects of adiponectin for hepatocytes have been widely examined ^[43]^[44]. Adiponectin exerts an anti-fibrotic and anti-inflammatory effect in LC ^[45]. A previous prospective study reported that adiponectin was associated with the degree of liver decompensation and worse prognosis in LC patients ^[46]. Adiponectin levels are reported to be independently associated with sarcopenia in LC patients ^[47]. Leptin, on the other hand, reflects whole-body fat mass. Leptin is an adipokine that regulates energy balance and glucose homeostasis. Obesity causes leptin resistance, which is thought to be indirectly related to sarcopenia through insulin resistance and other mechanisms ^[41]. In obesity-associated fatty liver, leptin induces CD14 expression via activation of STAT3 signaling in Kupffer cells, leading to marked inflammation and fibrosis by increasing the responsiveness of the liver to low dose of endotoxin ^[48].

Ectopic fat accumulation and SMM decline may exist in a vicious cycle due to their mutual influence ^[18]. Sarcopenia reduces physical activity, leading to energy expenditure loss and the elevated risk of obesity ^[19]. In contrast, increase of a visceral fat induces inflammation, contributing to the sarcopenia incidence ^[49]. Kim et al. reported, in a longitudinal study, that visceral obesity was associated with future SMM decline in Korean individuals ^[50]. In male cirrhotic patients with hepatocellular carcinoma (HCC) undergoing liver transplantation, a visceral adipose tissue ≥ 65 cm²/m² raised the risk of HCC recurrence more than five times ^[51]. Accumulation of subcutaneous adipose tissue can be an adverse predictor in patients with alcoholic LC ^[52]. High subcutaneous adipose tissue density and high visceral adipose tissue density on CT significantly correlated negatively with survival in HCC patients ^[53].

It has been widely accepted that the inhibition of myostatin contributes to reduced adipose tissue, indicating myostatin acts either directly or indirectly on adipose tissue ^[54]. Myostatin also has the effect of inhibition of protein synthesis in skeletal muscle ^[55]. Increased myostatin levels have been associated with both obesity and insulin resistance ^[56]^[57]^[58]. Serum myostatin levels can be lowered by aerobic exercise ^[58]. Resistance training can reduce myostatin levels, leading to the improvement of insulin resistance ^[59]. Hittel et al. reported that extremely obese individuals have been reported to have a 35% increase in plasma mature myostatin level and a 23% increase in skeletal muscle precursor myostatin level, as compared to lean controls, and BMI strongly correlated with myostatin level in skeletal muscle ^[56]. Visceral fat area, HbA1c, myostatin, and leptin are reported to be contributing factors associated with increased liver fat accumulation in patients with non-obese NAFLD ^[60]. Ammonia is a cytotoxic substance produced via several physiological processes, such as amino acid catabolism and gut microbiota metabolism ^[61]. The hepatocyte is the only cell that is able to metabolize ammonia to urea, which is a nontoxic metabolite being excreted by the kidneys. The enzymes that catalyze the urea cycle are zinc-containing enzymes, and when zinc deficiency occurs, ammonia processing is reduced. Most LC patients have zinc deficiency ^[62]. In LC patients, due to liver dysfunction and portosystemic shunts, serum ammonia concentrations tend to increase ^[56]. In our previous data in LC patients, serum myostatin level significantly increased with the worsening of liver function and the increase of serum ammonia level, and was associated with clinical outcomes ^[55]. Higher serum ammonia level can cause higher myostatin level in skeletal muscle, resulting in the progression of sarcopenia through the suppression of muscle protein synthesis ^[55].

Growth hormone (GH), as well as insulin-like growth factor (IGF)-1, regulates the growth of tissues, including skeletal muscle. Fatty acids inhibit the production of GH and decrease IGF-1 levels. The anabolic hormone IGF-1 is also involved in the regulation of GH, and IGF-1 acts in response to GH. IGF-1 decreases with increasing fat mass. In obese individuals, these anabolic hormones are decreased, and these decreases may be related to skeletal muscle disorders. LC is a condition of acquired resistance to GH. Impaired GH-IGF-1 system in LC can lead to LC-related complications ^[63]. In LC patients, IGF-1 level was correlated with the degree of liver dysfunction ^[63].

5. Myosteatosis and Liver Diseases

Myosteatosis refers to the pathological fat accumulation in skeletal muscle within the muscular fibers or within the fascia of the skeletal muscle ^[64]. Myosteatosis is associated with insulin resistance and type 2 diabetes mellitus ^[65]. Myosteatosis meditates inflammatory responses and can be linked to decreased muscle function and SMM decline caused by muscle atrophy and physical disabilities ^[66]^[67].

Myosteatosis in LC patients increased the risk of death by 1.5-to 2-fold, mainly due to the higher incidence of sepsis-related death ^[20]. Kaibori et al., reported, in their 141 HCC patients undergoing hepatectomy, that the five-year overall survival (OS) rates in patients with and without higher intramuscular adipose tissue content (IMAC) were 46% and 75%, and the five-year disease-free survival rates in patients with and without higher IMAC were 18 and 38%, and that higher IMAC was an independent predictor for OS in their multivariate analysis ^[21]. They also reported the significant correlation between higher IMAC and liver dysfunction, a higher amount of intraoperative blood loss, and complications of diabetes mellitus ^[21]. Another Japanese study reported the close correlation between higher IMAC and bacteremia after liver transplantation ^[68]. A significant correlation between preoperative higher IMAC and pulmonary dysfunction after hepatectomy was also reported ^[69]. Meanwhile, Bhanji et al. reported, in their LC subjects (n = 675), that myosteatosis was identified in 348 patients (52%), sarcopenia in 242 (36%), and hepatic encephalopathy in 128 (19%), and in their multivariable analysis, both myosteatosis and sarcopenia were independent factors for hepatic encephalopathy (HR = 2.25 and 2.42; p-values both < 0.01) ^[70].

References

Albano, D.; Messina, C.; Vitale, J.; Sconfienza, L.M. Imaging of sarcopenia: Old evidence and new insights. Eur. Radiol. 2020, 30, 2199–2208.
Rosenberg, I. Summary comments: Epidemiological and methodological problems in determining nutritional status of older persons. Am. J. Clin. Nutr. 1989, 50, 1231–1233.
Cruz-Jentoft, A.J.; Bahat, G.; Bauer, J.; Boirie, Y.; Bruyère, O.; Cederholm, T.; Cooper, C.; Landi, F.; Rolland, Y.; Sayer, A.A.; et al. Writing group for the european working group on sarcopenia in older people 2 (EWGSOP2), and the extended group for EWGSOP2. Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing. 2019, 48, 16–31.
Chen, L.K.; Woo, J.; Assantachai, P.; Auyeung, T.W.; Chou, M.Y.; Iijima, K.; Jang, H.C.; Kang, L.; Kim, M.; Kim, S.; et al. Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J. Am. Med. Dir. Assoc. 2020, 21, 300–307.
Nishikawa, H.; Enomoto, H.; Nishiguchi, S.; Iijima, H. Liver cirrhosis and sarcopenia from the viewpoint of dysbiosis. Int. J. Mol. Sci. 2020, 21, 5254.
Moriwaki, H.; Miwa, Y.; Tajika, M.; Kato, M.; Fukushima, H.; Shiraki, M. Branched-chain amino acids as a protein- and energy-source in liver cirrhosis. Biochem. Biophys. Res. Commun. 2004, 313, 405–409.
Kawaguchi, T.; Nagao, Y.; Matsuoka, H.; Ide, T.; Sata, M. Branched-chain amino acid-enriched supplementation improves insulin resistance in patients with chronic liver disease. Int. J. Mol. Med. 2008, 22, 105–112.
Dasarathy, S. Consilience in sarcopenia of cirrhosis. J. Cachexia Sarcopenia Muscle 2012, 3, 225–237.
Hanai, T.; Shiraki, M.; Ohnishi, S.; Miyazaki, T.; Ideta, T.; Kochi, T.; Imai, K.; Suetsugu, A.; Takai, K.; Moriwaki, H.; et al. Rapid skeletal muscle wasting predicts worse survival in patients with liver cirrhosis. Hepatol. Res. 2016, 46, 743–751.
Baumgartner, R.N. Body composition in healthy aging. Ann. NY Acad. Sci. 2000, 904, 437–448.
Wannamethee, S.G.; Atkins, J.L. Muscle loss and obesity: The health implications of sarcopenia and sarcopenic obesity. Proc. Nutr. Soc. 2015, 74, 405–412.
Li, J.; Zou, B.; Yeo, Y.H.; Feng, Y.; Xie, X.; Lee, D.H.; Fujii, H.; Wu, Y.; Kam, L.Y.; Ji, F.; et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-–2019: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2019, 4, 389–398.
World Health Organization (WHO). Obesity and Overweight Factsheet from the WHO; World Health Organization: Geneva, Switzerland, 2017.
The Asia-Pacific Perspective: Redefining Obesity and its Treatment; Word Health Organisation: Geneva, Switzerland, 2000.
Spengler, E.K.; O’Leary, J.G.; Te, H.S.; Rogal, S.; Pillai, A.A.; Al-Osaimi, A.; Desai, A.; Fleming, J.N.; Ganger, D.; Seetharam, A.; et al. Liver transplantation in the obese cirrhotic patient. Transplantation 2017, 101, 2288–2296.
Karagozian, R.; Bhardwaj, G.; Wakefield, D.B.; Baffy, G. Obesity paradox in advanced liver disease: Obesity is associated with lower mortality in hospitalized patients with cirrhosis. Liver Int. 2016, 36, 1450–1456.
Kumar, N.; Choudhary, N.S. Treating morbid obesity in cirrhosis: A quest of holy grail. World J. Hepatol. 2015, 7, 2819–2828.
Kim, T.N.; Choi, K.M. The implications of sarcopenia and sarcopenic obesity on cardiometabolic disease. J. Cell Biochem. 2015, 116, 1171–1178.
Zamboni, M.; Mazzali, G.; Fantin, F.; Rossi, A.; di Francesco, V. Sarcopenic obesity: A new category of obesity in the elderly. Nutr. Metab. Cardiovasc. Dis. 2008, 18, 388–395.
Montano-Loza, A.J.; Angulo, P.; Meza-Junco, J.; Prado, C.M.; Sawyer, M.B.; Beaumont, C.; Esfandiari, N.; Ma, M.; Baracos, V.E. Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. J. Cachexia Sarcopenia Muscle 2016, 7, 126–135.
Kaibori, M.; Ishizaki, M.; Iida, H.; Matsui, K.; Sakaguchi, T.; Inoue, K.; Mizuta, T.; Ide, Y.; Iwasaka, J.; Kimura, Y.; et al. Effect of intramuscular adipose tissue content on prognosis in patients undergoing hepatocellular carcinoma resection. J. Gastrointest. Surg. 2015, 19, 1315–1323.
Kobayashi, A.; Kaido, T.; Hamaguchi, Y.; Okumura, S.; Shirai, H.; Yao, S.; Kamo, N.; Yagi, S.; Taura, K.; Okajima, H.; et al. Impact of Sarcopenic Obesity on Outcomes in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma. Ann. Surg. 2019, 269, 924–931.
Carias, S.; Castellanos, A.L.; Vilchez, V.; Nair, R.; Dela Cruz, A.C.; Watkins, J.; Barrett, T.; Trushar, P.; Esser, K.; Gedaly, R. Nonalcoholic steatohepatitis is strongly associated with sarcopenic obesity in patients with cirrhosis undergoing liver transplant evaluation. J. Gastroenterol. Hepatol. 2016, 31, 628–633.
Hara, N.; Iwasa, M.; Sugimoto, R.; Mifuji-Moroka, R.; Yoshikawa, K.; Terasaka, E.; Hattori, A.; Ishidome, M.; Kobayashi, Y.; Hasegawa, H.; et al. Sarcopenia and sarcopenic obesity are prognostic factors for overall survival in patients with cirrhosis. Intern. Med. 2016, 55, 863–870.
Hammad, A.; Kaido, T.; Hamaguchi, Y.; Okumura, S.; Kobayashi, A.; Shirai, H.; Kamo, N.; Yagi, S.; Uemoto, S. Impact of sarcopenic overweight on the outcomes after living donor liver transplantation. Hepatobiliary Surg. Nutr. 2017, 6, 367.
Kamo, N.; Kaido, T.; Hamaguchi, Y.; Okumura, S.; Kobayashi, A.; Shirai, H.; Yao, S.; Yagi, S.; Uemoto, S. Impact of sarcopenic obesity on outcomes in patients undergoing living donor liver transplantation. Clin. Nutr. 2019, 38, 2202–2209.
Kroh, A.; Uschner, D.; Lodewick, T.; Eickhoff, R.M.; Schöning, W.; Ulmer, F.T.; Neumann, U.P.; Binnebösel, M. Impact of body composition on survival and morbidity after liver resection in hepatocellular carcinoma patients. Hepatobiliary Pancreat Dis. Int. 2019, 18, 28–37.
Bering, T.; Diniz, K.G.D.; Coelho, M.P.P.; Vieira, D.A.; Soares, M.M.S.; Kakehasi, A.M.; Correia, M.I.T.D.; Teixeira, R.; Queiroz, D.M.M.; Rocha, G.A.; et al. Association between pre-sarcopenia, sarcopenia, and bone mineral density in patients with chronic hepatitis C. J. Cachexia Sarcopenia Muscle 2018, 9, 255–268.
Vidot, H.; Kline, K.; Cheng, R.; Finegan, L.; Lin, A.; Kempler, E.; Strasser, S.I.; Bowen, D.G.; McCaughan, G.W.; Carey, S.; et al. The relationship of obesity, nutritional status and muscle wasting in patients assessed for liver transplantation. Nutrients 2019, 11, 2097.
Muto, Y.; Sato, S.; Watanabe, A.; Moriwaki, H.; Suzuki, K.; Kato, A.; Kato, M.; Nakamura, T.; Higuchi, K.; Nishiguchi, S.; et al. Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol. Res 2006, 35, 204–214.
Moriishi, K.; Mochizuki, R.; Moriya, K.; Miyamoto, H.; Mori, Y.; Abe, T.; Murata, S.; Tanaka, K.; Miyamura, T.; Suzuki, T.; et al. Critical role of PA28gamma in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. Proc. Natl. Acad. Sci. USA 2007, 104, 1661–1666.
Shintani, Y.; Fujie, H.; Miyoshi, H.; Tsutsumi, T.; Tsukamoto, K.; Kimura, S.; Moriya, K.; Koike, K. Hepatitis C virus infection and diabetes: Direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004, 126, 840–848.
Streba, L.A.; Vere, C.C.; Rogoveanu, I.; Streba, C.T. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: An open question. World J. Gastroenterol. 2015, 21, 4103–4110.
Cleasby, M.E.; Jamieson, P.M.; Atherton, P.J. Insulin resistance and sarcopenia: Mechanistic links between common co-morbidities. J. Endocrinol. 2016, 229, R67–R81.
Han, E.; Lee, Y.H.; Kim, B.K.; Park, J.Y.; Kim, D.Y.; Ahn, S.H.; Lee, B.W.; Kang, E.S.; Cha, B.S.; Han, K.H.; et al. Sarcopenia is associated with the risk of significant liver fibrosis in metabolically unhealthy subjects with chronic hepatitis B. Aliment Pharmacol. Ther. 2018, 48, 300–312.
Petta, S.; Ciminnisi, S.; di Marco, V.; Cabibi, D.; Cammà, C.; Licata, A.; Marchesini, G.; Craxì, A. Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2017, 45, 510–518.
Lee, Y.H.; Kim, S.U.; Song, K.; Park, J.Y.; Kim, D.Y.; Ahn, S.H.; Lee, B.W.; Kang, E.S.; Cha, B.S.; Han, K.H. Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008–2011). Hepatology 2016, 63, 776–786.
Koyama, Y.; Brenner, D.A. Liver inflammation and fibrosis. J. Clin. Investig. 2017, 127, 55–64.
Powers, S.K.; Smuder, A.J.; Judge, A.R. Oxidative stress and disuse muscle atrophy: Cause or consequence? Curr. Opin. Clin. Nutr. Metab. Care 2012, 15, 240–245.
Sinclair, M.; Grossmann, M.; Hoermann, R.; Angus, P.W.; Gow, P.J. Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: A randomised controlled trial. J. Hepatol. 2016, 65, 906–913.
Sakuma, K.; Yamaguchi, A. Sarcopenic obesity and endocrinal adaptation with age. Int. J. Endocrinol. 2013, 2013, 204164.
Barbara, P.; Maja, P.; Anna, L.; Małgorzata, G.; Beata, P.; Arkadiusz, O. TNF-α and IFN-s-dependent muscle decay is linked to NF-κB- and STAT-1α-stimulated Atrogin1 and MuRF1 genes in C2C12 myotubes. Mediators Inflamm. 2013, 2013, 171437.
Silva, T.E.; Colombo, G.; Schiavon, L.L. Adiponectin: A multitasking player in the field of liver diseases. Diabetes Metab. 2014, 40, 95–107.
Finelli, C.; Tarantino, G. What is the role of adiponectin in obesity related non-alcoholic fatty liver disease? World J. Gastroenterol. 2013, 19, 802–812.
Park, P.H.; Sanz-Garcia, C.; Nagy, L.E. Adiponectin as an anti-fibrotic and anti-inflammatory adipokine in the liver. Curr. Pathobiol. Rep. 2015, 3, 243–252.
Da Silva, T.E.; Costa-Silva, M.; Correa, C.G.; Denardin, G.; Alencar, M.L.A.; Coelho, M.S.P.H.; Muraro-Wildner, L.; Luiza-Bazzo, M.; González-Chica, D.A.; Dantas-Correa, E.B.; et al. Clinical significance of serum adiponectin and resistin levels in liver cirrhosis. Ann. Hepatol. 2018, 17, 286–299.
Zhao, M.; Zhou, X.; Yuan, C.; Li, R.; Ma, Y.; Tang, X. Association between serum irisin concentrations and sarcopenia in patients with liver cirrhosis: A cross-sectional study. Sci. Rep. 2020, 10, 16093.
Imajo, K.; Fujita, K.; Yoneda, M.; Nozaki, Y.; Ogawa, Y.; Shinohara, Y.; Kato, S.; Mawatari, H.; Shibata, W.; Kitani, H.; et al. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. Cell Metabolism 2012, 16, 44–54.
Gregor, M.F.; Hotamisligil, G.S. Inflammatory mechanisms in obesity. Annu. Rev. Immunol. 2011, 29, 415–445.
Kim, T.N.; Park, M.S.; Ryu, J.Y.; Choi, H.Y.; Hong, H.C.; Yoo, H.J.; Kang, H.J.; Song, W.; Park, S.W.; Baik, S.H.; et al. Impact of visceral fat on skeletal muscle mass and vice versa in a prospective cohort study: The Korean Sarcopenic Obesity Study (KSOS). PLoS ONE 2014, 9, e115407.
Montano-Loza, A.J.; Mazurak, V.C.; Ebadi, M.; Meza-Junco, J.; Sawyer, M.B.; Baracos, V.E.; Kneteman, N. Visceral adiposity increases risk for hepatocellular carcinoma in male patients with cirrhosis and recurrence after liver transplant. Hepatology 2018, 67, 914–923.
Sakamaki, A.; Yokoyama, K.; Koyama, K.; Morita, S.; Abe, H.; Kamimura, K.; Takamura, M.; Terai, S. Obesity and accumulation of subcutaneous adipose tissue are poor prognostic factors in patients with alcoholic liver cirrhosis. PLoS ONE 2020, 15, e0242582.
Von Hessen, L.; Roumet, M.; Maurer, M.H.; Lange, N.; Reeves, H.; Dufour, J.F.; Radu, P. High subcutaneous adipose tissue density correlates negatively with survival in patients with hepatocellular carcinoma. Liver Int. 2020.
Tang, L.; Liu, C.T.; Wang, X.D.; Luo, K.; Zhang, D.D.; Chi, A.P.; Zhang, J.; Sun, L.J. A prepared anti-MSTN polyclonal antibody reverses insulin resistance of diet-induced obese rats via regulation of PI3K/Akt/mTOR&FoxO1 signal pathways. Biotechnol. Lett. 2014, 36, 2417–2423.
Nishikawa, H.; Enomoto, H.; Ishii, A.; Iwata, Y.; Miyamoto, Y.; Ishii, N.; Yuri, Y.; Hasegawa, K.; Nakano, C.; Nishimura, T.; et al. Elevated serum myostatin level is associated with worse survival in patients with liver cirrhosis. J. Cachexia Sarcopenia Muscle 2017, 8, 915–925.
Hittel, D.S.; Berggren, J.R.; Shearer, J.; Boyle, K.; Houmard, J.A. Increased secretion and expression of myostatin in skeletal muscle from extremely obese women. Diabetes 2009, 58, 30–38.
Hjorth, M.; Pourteymour, S.; Görgens, S.W.; Langleite, T.M.; Lee, S.; Holen, T.; Gulseth, H.L.; Birkeland, K.I.; Jensen, J.; Drevon, C.A.; et al. Myostatin in relation to physical activity and dysglycaemia and its effect on energy metabolism in human skeletal muscle cells. Acta Physiol. 2016, 217, 45–60.
Guo, T.; Jou, W.; Chanturiya, T.; Portas, J.; Gavrilova, O.; McPherron, A.C. Myostatin inhibition in muscle, but not adipose tissue, decreases fat mass and improves insulin sensitivity. PLoS ONE 2009, 4, e4937.
Shabkhiz, F.; Khalafi, M.; Rosenkranz, S.; Karimi, P.; Moghadami, K. Resistance training attenuates circulating FGF-21 and myostatin and improves insulin resistance in elderly men with and without type 2 diabetes mellitus: A randomised controlled clinical trial. Eur. J. Sport Sci. 2020, 1–10.
Shida, T.; Oshida, N.; Suzuki, H.; Okada, K.; Watahiki, T.; Oh, S.; Kim, T.; Isobe, T.; Okamoto, Y.; Ariizumi, S.I.; et al. Clinical and anthropometric characteristics of non-obese non-alcoholic fatty liver disease subjects in Japan. Hepatol. Res. 2020, 50, 1032–1046.
Qiu, J.; Thapaliya, S.; Runkana, A.; Yang, Y.; Tsien, C.; Mohan, M.L.; Narayanan, A.; Eghtesad, B.; Mozdziak, P.E.; McDonald, C.; et al. Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-kappaB-mediated mechanism. Proc. Natl. Acad. Sci. USA 2013, 110, 18162–18167.
Nishikawa, H.; Enomoto, H.; Yoh, K.; Iwata, Y.; Sakai, Y.; Kishino, K.; Ikeda, N.; Takashima, T.; Aizawa, N.; Takata, R.; et al. Serum zinc concentration and sarcopenia: A close linkage in chronic liver diseases. J. Clin. Med. 2019, 8, 336.
Colakoğlu, O.; Taşkiran, B.; Colakoğlu, G.; Kizildağ, S.; Ari Ozcan, F.; Unsal, B. Serum insulin like growth factor-1 (IGF-1) and insulin like growth factor binding protein-3 (IGFBP-3) levels in liver cirrhosis. Turk. J. Gastroenterol. 2007, 18, 245–249.
Miljkovic, I.; Zmuda, J.M. Epidemiology of myosteatosis. Curr. Opin. Clin. Nutr. Metab. Care. 2010, 13, 260–264.
Zoico, E.; Corzato, F.; Bambace, C.; Rossi, A.P.; Micciolo, R.; Cinti, S.; Harris, T.B.; Zamboni, M. Myosteatosis and myofibrosis: Relationship with aging, inflammation and insulin resistance. Arch. Gerontol. Geriatr. 2013, 57, 411–416.
Reinders, I.; Murphy, R.A.; Brouwer, I.A.; Visser, M.; Launer, L.; Siggeirsdottir, K.; Eiriksdottir, G.; Gudnason, V.; Jonsson, P.V.; Lang, T.F.; et al. Age, gene/environment susceptibility (AGES)-reykjavik study. muscle quality and myosteatosis: Novel associations with mortality risk: The age, gene/environment susceptibility (AGES)-reykjavik study. Am. J. Epidemiol. 2016, 183, 53–60.
Correa-de-Araujo, R.; Addison, O.; Miljkovic, I.; Goodpaster, B.H.; Bergman, B.C.; Clark, R.V.; Elena, J.W.; Esser, K.A.; Ferrucci, L.; Harris-Love, M.O.; et al. Myosteatosis in the context of skeletal muscle function deficit: An interdisciplinary workshop at the national institute on aging. Front. Physiol. 2020, 11, 963.
Kamo, N.; Kaido, T.; Miyachi, Y.; Iwamura, S.; Yao, S.; Shirai, H.; Yagi, S.; Uemoto, S. Preoperative abnormal body composition is closely related to bacteremia after living donor liver transplantation. Nutrition 2020, 77, 110798.
Shirai, H.; Kaido, T.; Hamaguchi, Y.; Kobayashi, A.; Okumura, S.; Yao, S.; Yagi, S.; Kamo, N.; Taura, K.; Okajima, H.; et al. preoperative low muscle mass and low muscle quality negatively impact on pulmonary function in patients undergoing hepatectomy for hepatocellular carcinoma. Liver Cancer 2018, 7, 76–89.
Bhanji, R.A.; Moctezuma-Velazquez, C.; Duarte-Rojo, A.; Ebadi, M.; Ghosh, S.; Rose, C.; Montano-Loza, A.J. Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with cirrhosis. Hepatol. Int. 2018, 12, 377–386.

© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.

Upload a video for this entry

Information

Subjects: Gastroenterology & Hepatology

Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :

Hiroki Nishikawa

View Times: 371

Update Date: 20 Apr 2021

Table of Contents

Video Upload Options

Confirm